Kenney Christopher John's Form 4 filing
Xenon Pharmaceuticals Inc. (XENE) · filed Mar 11, 2026
- Accession no.
- 0001193125-26-102669
- Filed
- Mar 11, 2026
- Trade date
- Mar 9-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $166.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kenney Christopher JohnCIK 0001880129 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Common Shares | MOption exerciseAcquired | +7,500 | –F1 | – | 7,500 | Direct | |
| Mar 10, 2026 | Common Shares | SSaleDisposed | −2,771 | $60.11 | −$166,564.81 | 4,729 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Common Shares | AGrant or awardAcquired | +7,500 | $0.00 | $0 | 7,500 | Direct | |
| Mar 9, 2026 | Common Shares | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents shares earned and vested under a performance share unit ("PSU") award granted to the reporting person on March 11, 2024. The number of shares earned is based on a determination by the issuer's Board of Directors of the achievement of one or more prescribed milestones under the terms of the PSU award agreement. The PSUs vested immediately upon such determination.
Referenced by the price of 1 transaction in Table I.